SCHEMBL7572347

SCHEMBL7572347

COC(=O)CCc1c(-c2ccc(Cl)cc2)[nH]c2ccc(Cl)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
EGFR P00533 2/20 0.44
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42
TACR1 P25103 6/20 0.41
SRC P12931 1/20 0.40
TSPO P30536 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7659833 0.78 TACR1 (0.45) MTNR1AMTNR1BEGFRTACR1SRC
SCHEMBL7657110 0.76 HTR6 (0.48) MTNR1AMTNR1BEGFRTACR1SRC
SCHEMBL7790369 0.76 CXCR2 (0.52) MTNR1AMTNR1BEGFRTACR1SRC
SCHEMBL7655822 0.75 TACR1 (0.56) TACR1CYP11B1CYP11B2KDM4EALDH1A1
SCHEMBL7575218 0.75 MTNR1A (0.47) MTNR1AEGFRCCNB2CDK1CCNB1
SCHEMBL7798973 0.74 TACR1 (0.48) MTNR1AMTNR1BEGFRTACR1SRC
SCHEMBL7238513 0.74 TSPO (0.56) TACR1TSPOKDM4EALDH1A1HPGD
SCHEMBL7233182 0.72 TACR1 (0.50) MTNR1AMTNR1BEGFRTACR1SRC
SCHEMBL6805872 0.71 TSPO (0.47) MTNR1AMTNR1BTACR1TSPOKDM4E
SCHEMBL7253117 0.71 GSK3A (0.69) CCNB2CDK1CCNB1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6476045-B2 INDOLE AND AZAINDOLE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS, AND IN PARTICULAR AS NEUROKININ-1 RECEPTOR ANTAGONIST MERCK SHARP & DOHME LTD. (GB) 2002-11-05 US disclosed
US-20020022624-A1 Azaindole derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2002-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022624-A1 Azaindole derivatives and their use as therapeutic agents HTR2B, HNMT, HTR1B MTNR1A 356/4885MTNR1B 145/4885EGFR 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.